Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Advance Jr: efgartigimod IV in adolescents with chronic immune thrombocytopenia
jRCT2051260154Recruiting
- Sponsor
- argenx
- Start
- Sep 2026
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Randomised, double-blind trial in immune thrombocytopenia (ITP) comparing Efgartigimod IV with Placebo IV (2 arms). Primary endpoints: Efgartigimod serum concentrations in the DBTP and Total IgG levels in the DBTP. Started Sep 2026; status: recruiting.
02
Drugs
efgartigimod alfa
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on jRCT2051260154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051260154.